Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia

Brian Mejak, Carmen Giacomuzzi, Eileen Heller, Xiaomang You, Ross Ungerleider, Irving Shen, Lynn Boshkov

Research output: Contribution to journalArticlepeer-review

46 Scopus citations


We report a post-Norwood Stage I patient requiring ECMO support using Argatroban as an anticoagulant following diagnosis of heparin-induced thrombocytopenia (HIT). A 2.6 kg female was born with hypoplastic left heart syndrome and underwent a Norwood Stage I operation on day 4 of life. The patient weaned off cardiopulmonary bypass with no complications and was routinely placed on a ventricular assist device (VAD) for 3 days. Heparin was infused at a rate of 16-32 IU/kg/h to maintain an ACT of 160-180 seconds. Two days after VAD termination, the patient was placed on continuous veno-veno hemofiltration (CVVH). Shortly after CVVH, the patient was diagnosed with HIT and placed on an Argatroban infusion. Five days later, a VAD and subsequent ECMO was used because of decreasing left ventricular function, gross body edema, and poor renal function. This case report summarizes the use of Argatroban during VAD and ECMO support for a patient diagnosed with HIT.

Original languageEnglish (US)
Pages (from-to)178-181
Number of pages4
JournalJournal of Extra-Corporeal Technology
Issue number2
StatePublished - Jun 1 2004


  • Anticoagulant
  • Argatroban
  • Extracorporeal membrane oxygenation

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Health Professions (miscellaneous)
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia'. Together they form a unique fingerprint.

Cite this